Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy

Nuclear Medicine and Biology

Volumn 33, Issue 2, 2006, Pages 271-279

  Dahle, Jostein ^a   Borrebæk, Jørgen ^b   Melhus, Katrine B ^a   Bruland, Øyvind S ^a,c   Salberg, Gro ^b   Olsen, Dag Rune ^a   Larsen, Roy H ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Algeta AS   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Alpha radiation; Lymphoma; Radioimmunotherapy; Rituximab; Thorium 227

Indexed keywords

RITUXIMAB; THORIUM 227; THORIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL GROWTH; CHELATION; CONTROLLED STUDY; EVALUATION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOTHERAPY; LYMPHOMA CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR CELL;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; LYMPHOMA; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 33644942120     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.12.004     Document Type: Article

References (29)

1. B.D. Cheson What is new in lymphoma? CA Cancer J Clin 54 2004 260 272
2. J.O. Armitage Treatment of non-Hodgkin's lymphoma N Engl J Med 328 1993 1023 1030
3. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, and M.E. Williams Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825 2833
4. 131I-Tositumomab therapy as initial treatment for follicular lymphoma N Engl J Med 352 2005 441 449
5. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 96 2000 1259 1266
6. R. Schilder, A. Molina, N. Bartlett, T. Witzig, L. Gordon, and J. Murray Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia Cancer Biother Radiopharm 19 2004 478 481
7. L.I. Gordon, T. Witzig, A. Molina, M. Czuczman, C. Emmanouilides, and R. Joyce Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma Clin Lymphoma 5 2004 98 101
8. 211At-rituximab against non-Hodgkin's lymphoma cells Br J Cancer 83 2000 1375 1379
9. G. Henriksen, P. Hoff, and R.H. Larsen Evaluation of potential chelating agents for radium Appl Radiat Isot 56 2002 667 671
10. M.R. McDevitt, D. Ma, L.T. Lai, J. Simon, P. Borchardt, and R.K. Frank Tumor therapy with targeted atomic nanogenerators Science 294 2001 1537 1540
11. M. Miederer, M.R. McDevitt, P. Borchardt, I. Bergman, K. Kramer, and N.K. Cheung Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2 Clin Cancer Res 10 2004 6985 6992
12. J.S. Jaggi, S.V. Seshan, M.R. McDevitt, K. Laperle, G. Sgouros, and D.A. Scheinberg Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters J Am Soc Nephrol 16 2005 2677 2689
13. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence-Bruckler, D. Maloney, and M. Czuczman Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 9 1998 995 1001
14. S. Nilsson, R.H. Larsen, S.D. Fossa, L. Balteskard, K.W. Borch, and J.E. Westlin First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin Cancer Res 11 2005 4451 4459
15. E.J. Hall Radiobiology for the radiologist 4th ed. 2000 Lippincott Philadelphia
16. 227Th source Radiochim Acta 89 2001 661 666
17. G. Henriksen, O.S. Bruland, and R.H. Larsen Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents Anticancer Res 24 2004 101 105
18. T. Lindmo, and P.A. Bunn Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling Methods Enzymol 121 1986 678 691
19. Nuclide explorer 2000 Institute for Transuranium Elements Karlsruhe (Germany)
20. J. Yuan Estimation of variance for AUC in animal studies J Pharm Sci 82 1993 761 763
21. 89Sr in mice J Nucl Med 44 2003 252 259
22. R.W. Howell, S.M. Goddu, V.R. Narra, D.R. Fisher, R.E. Schenter, and D.V. Rao Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo Radiat Res 147 1997 342 348
23. 223Ra demonstrated in an experimental skeletal metastases model Cancer Res 62 2002 3120 3125
24. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation J Nucl Med 40 1999 1197 1203
25. 125I-labeled amidobisphosphonates in mice Nucl Med Biol 26 1999 791 794
26. 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma Ann Oncol 16 2005 786 792
27. E. Aurlien, Y. Kvinnsland, R.H. Larsen, and O.S. Bruland Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation Int J Radiat Biol 78 2002 133 142
28. S.G. Sawant, G. Randers-Pehrson, N.F. Metting, and E.J. Hall Adaptive response and the bystander effect induced by radiation in C3H 10T(1/2) cells in culture Radiat Res 156 2001 177 180
29. Y. Kvinnsland, T. Stokke, and E. Aurlien Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei Radiat Res 155 2001 288 296